Selecting the correct on label or off label medication to treat obesity can be confusing. The acronym RXAOM provides a framework for individualizing the selection process.
|
Obesity is a metabolic disease that requires lifelong lifestyle changes and in many patients who are overweight or obese, prescription medication.
|
Here we are! At the Obesity the Tipping Point: the critical point in a process or system beyond which a significant and often unstoppable effect or change takes place.
|
Demand for pharmacotherapy has increased considerably with the introduction of newer anti-obesity medications (AOM’s).
|
This session will inform HCPs on the tirzepatide molecule, design of the SURMOUNT global trial program for the treatment of obesity and overweight, and safety and efficacy data disclosure for SURMO
|
Obesity pharmacotherapy often is solely equated as therapeutic use of anti-obesity medications (AOMs). In this session, two important factors in obesity pharmacotherapy will be discussed.
|
Poor responders to common medical weight loss treatments is a challenging situation for clinicians.
|
An important part of the Obesity Medicine provider’s practice, and one of the pillars of obesity care, is considering the use of medications for the treatment of overweight and obesity. Anti-obesi
|
Obesity Pharmacotherapy: Challenges & Barriers Using Anti-Obesity Medications (Recorded)
|
Over the last decade, the FDA has approved five new medications for the treatment of obesity. The latest edition, semaglutide, published impressive weight loss results and we are just beginning.
|